In Monday's analysts' actions, one Wall Street firm is weighing in on the Hewlett Packard split and another firm is giving Abbvie (ABBV) a rating and target price boost. Credit Suisse started coverage of HP Inc. (HPQ), one of the two companies from the HP split. Analysts gave the company an OUTPERFORM rating with a $19 price target. They said that HP Inc. has a 'solid franchise and a multi-faceted strategy to offset secular pressure in the printing and PC end-markets.' Another positive is that there will be a significant cash return to shareholders. The same firm began coverage of Hewlett Packard Enterprise (HPE), the other company from the HP separation. Analysts started coverage with a NEUTRAL rating and a $19 price target. They're more cautious about this one due to secular challenges in the IT market. But, the firm noted that the company has a strong balance sheet. In another note, Morgan Stanley upgraded Abbvie to OVERWEIGHT from EQUAL WEIGHT and lifted its price target to $73 from $62. The firm said 'AbbVie is now the cheapest large-cap pharma with superior long-term prospects.' TheStreet's U-Jin Lee reports from New York.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.